Literature DB >> 15257945

FIP1L1-PDGFRA and c-kit D816V mutation-based clonality studies in systemic mast cell disease associated with eosinophilia.

Ayalew Tefferi, Terra L Lasho, Stephanie R Brockman, Michelle A Elliott, Angela Dispenzieri, Animesh Pardanani.   

Abstract

Laboratory methods to detect both FIP1L1-PDGFRA and c-kit D816V mutations were combined with immunomagnetic cell separation to study the extent of clonal involvement by both myeloid and lymphoid cells in 3 patients with systemic mastocytosis associated with eosinophilia. The results suggested an early stem cell origin for the FIP1L1-PDGFRA mutation.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15257945

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


  6 in total

Review 1.  FIP1L1/PDGFR alpha-associated systemic mastocytosis.

Authors:  Yoshiyuki Yamada; Jose A Cancelas
Journal:  Int Arch Allergy Immunol       Date:  2010-06-04       Impact factor: 2.749

2.  The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like disease.

Authors:  Yoshiyuki Yamada; Marc E Rothenberg; Andrew W Lee; Hiroko Saito Akei; Eric B Brandt; David A Williams; Jose A Cancelas
Journal:  Blood       Date:  2006-01-17       Impact factor: 22.113

Review 3.  Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology.

Authors:  Cem Akin
Journal:  J Mol Diagn       Date:  2006-09       Impact factor: 5.568

4.  Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F.

Authors:  Karl Sotlar; Anja Bache; Florian Stellmacher; Burkhard Bültmann; Peter Valent; Hans-Peter Horny
Journal:  J Mol Diagn       Date:  2007-12-28       Impact factor: 5.568

5.  Current concepts on the pathogenesis of the hypereosinophilic syndrome/chronic eosinophilic leukemia.

Authors:  Yoshiyuki Yamada; Marc E Rothenberg; Jose A Cancelas
Journal:  Transl Oncogenomics       Date:  2006-12-05

Review 6.  Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.

Authors:  Ayalew Tefferi
Journal:  J Cell Mol Med       Date:  2008-10-23       Impact factor: 5.310
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.